Recombinant Human LIF

Name

Recombinant Human LIF (Recombinant Human Leukemia Inhibitory Factor; rHuLIF)；重组人白血病抑制因子

Synonyms

CDF; D factor; DIA; differentiation inhibitory activity; differentiation stimulating factor; Differentiation-stimulating factor; Emfilermin; HILDAcholinergic differentiation factor; leukemia inhibitory factor; leukemia inhibitory factor (cholinergic differentiation factor); Melanoma-derived LPL inhibitor; MLPLI

Purity

>98% by SDS-PAGE and HPLC analyses.

Biological Activity

Fully biologically active when compared to standard. The ED50 as determined by the dose-dependent proliferation of human TF-1 cells is less than 0.1ng/ml, corresponding to a specific activity of >1.0×10⁷IU/mg.

Physical Appearance

Sterile Filtered White lyophilized (freeze-dried) powder.

Formulation

Lyophilized from a 0.2μM filtered concentrated solution in PBS, pH7.4.

Endotoxin

Less than 1EU/μg of rHuLIF as determined by LAL method.

Reconstitution

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-0.2mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤-20℃. Further dilutions should be made in appropriate buffered solutions.

Category

Cytokine

Background

Leukemia inhibitory factor (LIF) is a member of Interleukin 6 family. This protein is mainly expressed in the trophectoderm of the developing embryo, with its receptor LIFR expressed throughout the inner cell mass. LIF has the capacity to induce terminal differentiation in leukemic cells. Its activities include the induction of hematopoietic differentiation in normal and myeloid leukemia cells, the induction of neuronal cell differentiation, and the stimulation of acute-phase protein synthesis in hepatocytes. LIF is used in mouse embryonic stem cell culture, because that removal of LIF pushes stem cells toward differentiation, but they retain their proliferative potential or pluripotency. It is also used in phase II clinical trial, which can assist embryo implantation in women who have failed to become pregnant despite assisted reproductive technologies (ART). Mature human LIF (180a.a.) shares 78%, 82%, 91%, 88% and 87%a.a. sequence identity with mouse, rat, canine, bovine, and porcine LIF, respectively.

Amino Acid Sequence

SPLPITPVNA TCAIRHPCHN NLMNQIRSQL AQLNGSANAL FILYYTAQGE PFPNNLDKLC GPNVTDFPPF HANGTEKAKL VELYRIVVYL GTSLGNITRD QKILNPSALS LHSKLNATAD ILRGLLSNVL CRLCSKYHVG HVDVTYGPDT SGKDVFQKKK LGCQLLGKYK QIIAVLAQAF

产品编号

产品名称

包装

KL-5354-5μg

Recombinant Human LIF

5μg

KL-5354-25μg

Recombinant Human LIF

25μg

KL-5354-100μg

Recombinant Human LIF

100μg

KL-5354-1mg

Recombinant Human LIF

1mg

-

说明书

1份